Novartis Snaps Up Cachexia Candidate On The Cheap As AVEO's Focus Returns to Tivozanib
This article was originally published in Scrip
Executive Summary
AVEO Oncology is seeing the resurgence in its fortunes continue with the signing of a licensing agreement with Novartis for its growth differentiation factor 15 (GDF15) inhibitory antibody AV-380, which is in preclinical development as a potential treatment for cachexia.